{"filing":{"accession_number":"0001140361-26-024997","cik":"0001281895","ticker":"RCKTW","company_name":"ROCKET PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"ef20076119_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126024997/ef20076119_8k.htm"},"events":[{"id":10388,"run_id":9110,"accession_number":"0001140361-26-024997","anchor_item_number":"2.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Rocket Pharmaceuticals completed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $180.0 million gross proceeds on June 10, 2026, pursuant to an asset purchase agreement dated April 26, 2026. This material asset disposition represents a significant one-time cash inflow affecting the company's liquidity and financial position.","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6692,"accession_number":"0001140361-26-024997","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material asset disposition—the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $180.0 million gross proceeds, closed on June 10, 2026 pursuant to an asset purchase agreement dated April 26, 2026. This is a significant one-time cash inflow that would materially affect investor assessment of the company's liquidity and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:32.522448+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6693,"accession_number":"0001140361-26-024997","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the closing of an \"Asset Sale\" via press release on June 12, 2026. Asset sales constitute material M\u0026A activity under Item 1.01/1.02 taxonomy, and the disclosure of a completed transaction closing would materially affect a reasonable investor's assessment of the company's asset base and financial position. The Item 7.01 disclosure vehicle (Regulation FD) is commonly used for M\u0026A announcements, though the specific nature and magnitude of the asset sale cannot be fully assessed from this excerpt alone.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:32.522448+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6692,"accession_number":"0001140361-26-024997","item_number":"2.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses completion of a material asset disposition—the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $180.0 million gross proceeds, closed on June 10, 2026 pursuant to an asset purchase agreement dated April 26, 2026. This is a significant one-time cash inflow that would materially affect investor assessment of the company's liquidity and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:32.522448+00:00","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-06-12"},{"id":6693,"accession_number":"0001140361-26-024997","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The filing discloses the closing of an \"Asset Sale\" via press release on June 12, 2026. Asset sales constitute material M\u0026A activity under Item 1.01/1.02 taxonomy, and the disclosure of a completed transaction closing would materially affect a reasonable investor's assessment of the company's asset base and financial position. The Item 7.01 disclosure vehicle (Regulation FD) is commonly used for M\u0026A announcements, though the specific nature and magnitude of the asset sale cannot be fully assessed from this excerpt alone.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:18:32.522448+00:00","company_name":"ROCKET PHARMACEUTICALS, INC.","ticker":"RCKTW","filing_date":"2026-06-12"}]}